Antigenics,Inc. is developing treatments for cancers, serius infectious diseases,autoimmune disorders and degenerative disorders, using the Company's proprietary technologies to program the immune system and improve quality of life. These products de immunotherapeutics basedon a specific class of heat shock proteins (HSPs), which activate powerful cellular immune responses, and St products,including QS-21, which activates superior antibody responses. At year-end 2000, the Company was evaluating its lead HSP-ased immunotherapeutic, Oncophage, in an international multi-center Phase III cancer, and in five additional cancer indications in ms and partnerships, the Company was also testing its Stimulon-based products in 11 Phase III and Phase II clinical trials for cancer, several infectious diseases and degenerative disorders.